Such data provide a rationale to combine MEK inhibitors and checkpoint inhibitors in RAS mutated tumors to enhance MHC class I molecule expression and to enhance tumor recognition by infiltrated CD8 T cells (39). This evidence concerns the gene CD8A and neoplasm.